Auspex Pharmaceuticals (Vista, CA) a clinical-stage small molecule company focused on deuterated analogs of clinically validated pain drugs, closed a $12M Series C financing. Participants have previously identified Thomas, McNerney & Partners, CMEA Ventures and Sloan Biotech Funds.